» Articles » PMID: 26801908

Estimating the Impact of Changes in HbA1c, Body Weight and Insulin Injection Regimen on Health Related Quality-of-life: a Time Trade off Study

Overview
Publisher Biomed Central
Specialty Public Health
Date 2016 Jan 24
PMID 26801908
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Background: There are limited data on the potential short-term benefits associated with reductions in HbA1c levels, and understanding any immediate improvements in health related quality-of-life (HRQoL) through better glycaemic control may help inform diabetes management decisions. This time-trade-off (TTO) study investigated the short-term impact on HRQoL associated with three different aspects of diabetes management; HbA1c change, body weight change, and the complexity of treatment regimen.

Methods: The study was designed in three stages: Stage 1) Qualitative telephone interviews with people with type 2 diabetes (T2D) in Denmark who had experienced a decrease in their HbA1c level. Stage 2) A validation survey with people with T2D in Denmark to obtain quantifiable knowledge on the short-term effects of a change in HbA1c levels. Stage 3) TTO survey using health states based on results from stage 2. Respondents were either adults with T2D (Sweden) or from the general public (UK and Denmark) and were separately asked to evaluate seven health states through an internet-based survey.

Results: Results from 4060 respondents were available for the TTO analysis (UK n = 1777; Denmark n = 1799, Sweden n = 484). 'Well-controlled diabetes' was associated with utilities of 0.85-0.91 and 'not well-controlled diabetes' with utilities of 0.71-0.80 in all countries. Difference in utilities per HbA1c percentage point was smallest in Sweden and largest in Denmark (between 0.025-0.034 per HbA1c percentage point respectively). The treatment management health state associated with the lowest disutility was the once-daily insulin regimen. The disutility associated with per kg of weight change ranged from 0.0041-0.0073.

Conclusions: Changes in HbA1c levels, insulin regimen and body weight are all likely to affect HRQoL for patients with T2D. A change in HbA1c is likely to have a short-term impact in addition to the effect on the development of long term diabetes complications. A treatment which has a simple regimen with fewer injections, and/or the need for less planning, and that causes weight loss or less weight gain, compared with other treatments, will have a positive impact on HRQoL.

Citing Articles

Health state utility values of type 2 diabetes mellitus and related complications: a systematic review and meta-regression.

Wang Y, Xu Y, Shan H, Pan H, Chen J, Yang J Health Qual Life Outcomes. 2024; 22(1):74.

PMID: 39244536 PMC: 11380328. DOI: 10.1186/s12955-024-02288-1.


A Qualitative Research Study of Experiences and Perceptions of People Living with Insulin Resistance Syndrome or Lipoatrophic Diabetes in Japan.

Yagi N, Toda A, Mitani K, Kotobuki Y, Ogawa W Diabetes Ther. 2023; 14(8):1345-1356.

PMID: 37289357 PMC: 10299960. DOI: 10.1007/s13300-023-01412-6.


Weight Loss Versus Glycemic Control as the Primary Treatment Target in Newly Diagnosed Type 2 Diabetes: Why Choose When You Can Have Both?.

Koufakis T, Liberopoulos E, Kokkinos A, Zebekakis P, Kotsa K Drugs. 2023; 83(6):469-477.

PMID: 36941489 DOI: 10.1007/s40265-023-01852-1.


Cost-effectiveness of metabolic surgery for the treatment of type 2 diabetes and obesity: a systematic review of economic evaluations.

Jordan K, Fawsitt C, Carty P, Clyne B, Teljeur C, Harrington P Eur J Health Econ. 2022; 24(4):575-590.

PMID: 35869383 PMC: 10175448. DOI: 10.1007/s10198-022-01494-2.


Evaluating the Impact of Therapy on Quality of Life in Type 2 Diabetes: A Literature Review of Utilities Associated with Treatment-Related Attributes.

Valentine W, Norrbacka K, Boye K Patient Relat Outcome Meas. 2022; 13:97-111.

PMID: 35586269 PMC: 9109803. DOI: 10.2147/PROM.S322390.


References
1.
. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group. Diabetes Care. 1999; 22(7):1125-36. DOI: 10.2337/diacare.22.7.1125. View

2.
Bagust A, Beale S . Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ. 2004; 14(3):217-30. DOI: 10.1002/hec.910. View

3.
Peyrot M, Barnett A, Meneghini L, Schumm-Draeger P . Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012; 29(5):682-9. PMC: 3433794. DOI: 10.1111/j.1464-5491.2012.03605.x. View

4.
Rubin R . Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med. 2005; 118 Suppl 5A:27S-34S. DOI: 10.1016/j.amjmed.2005.04.012. View

5.
. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):854-65. View